Why drug shortages are having an outsize impact on ovarian cancer patients
Sarah Evans considers herself a lucky ovarian cancer patient, though she is dealing with the second recurrence of the disease since she was first diagnosed in February 2018.
She is grateful that, even by her third round of chemo in March of this year, her cancer was still responding to carboplatin treatment — the most common first line of treatment for ovarian cancer, and one Evans tolerates without unbearable side effects. Patients often become resistant to carboplatin, especially after repeat treatments, in which case they require different drugs that may be less effective, or have more side effects.
Read Original Article: Why drug shortages are having an outsize impact on ovarian cancer patients »
